ClinicalTrials.gg
Active, not recruitingNCT06495424Updated Jul 13, 2026

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

An observational study in Peripheral Diabetic Neuropathy and Painful Diabetic Neuropathy, sponsored by Averitas Pharma, Inc.. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Averitas Pharma, Inc. (part of Grünenthal GmbH) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
144
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 158 studies in Diabetic Neuropathies with a site in United States — 12 open to participants now, 17 under way, none of them phase 3. Diabetic Neuropathies · United States.

Enrollment
6th of 11
144 · median 144
Started
2025
with 3 others
Observational
11 of 158
1 open now
Primary completion
2027-03
later than 10 of 16 live
Registered
149th of 158
by date

Among the 158 studies in Diabetic Neuropathies with a site in United States, this one is the 6th largest by enrollment of the 11 observational ones that give a count, is one of 4 that started in 2025, is one of 11 observational ones, reaches primary completion later than 10 of the 16 other live ones, and was the 149th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

12 of the 158 studies in Diabetic Neuropathies with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Diabetic Neuropathies with a site in United States, or all of them as a file.
02

Study summary

The purpose of this post-market observational study is to provide real-world evidence to support the repeated use of QUTENZA in patients with PDPN and to evaluate the potential for pain and concomitant medication use reduction.

03

Conditions studied

  • Peripheral Diabetic Neuropathy
  • Painful Diabetic Neuropathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients for inclusion in the study are those with PDPN as assessed by the Douleur Neuropathique 4 Interview (DN4I) assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. IRB approved written and privacy language as per national regulations will be obtained from the patient or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable)
  2. Male or female 18 - 80 years of age
  3. Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy due to diabetes confirmed by the Douleur Neuropathique 4 Interview (DN4I) of at least 3 out of 7
  4. Baseline PROMIS-29 numeric pain intensity score over the last 7 days ≥ 4 during the screening period
  5. Stable doses of pain medications for PDPN for more than 4 weeks prior to the screening visit
  6. Patient agreed not to participate in another interventional study while on treatment

Exclusion criteria

Exclusion Criteria:

  1. Pain associated with PDPN in the ankles or above
  2. Pain that could not be clearly differentiated from, or conditions that might have interfered with the assessment of the PDPN, such as plantar fasciitis, heel spurs, tibial neuropathy, Morton's neuroma, bunions, metatarsalgia, arthritis in feet, peripheral vascular disease (ischemic pain), neurological disorders unrelated to diabetic neuropathy (eg, phantom limb pain from amputation), skin condition in the area of the neuropathy that could alter sensation (eg, plantar ulcer)
  3. Significant pain (moderate or above) of an etiology other than PDPN (eg, compression-related neuropathies [eg, spinal stenosis]), fibromyalgia or arthritis, that may interfere with assessment of PDPN-related pain
  4. Current foot ulcer or not intact skin as determined by medical examination
  5. foot deformities or foot amputations
  6. Any active signs of skin inflammation around onychomycosis sites such as pain, redness, swelling or drainage
  7. Patient is unwilling to implement proper foot care methods
  8. Diagnosis of any poorly controlled major psychiatric disorder at the Investigator's discretion
  9. Evidence of cognitive impairment including dementia that may interfere with patient's ability to complete pain assessments requiring patient's recall of average pain level in the past 24 hours
  10. Active substance abuse or history of chronic substance abuse within 1 year prior to screening visit or any prior chronic substance abuse (including alcoholism) likely to have reoccurred during the study period as judged by the Investigator
  11. Participation in any other PDPN related clinical study within 30 days prior to the screening visit
  12. Previous treatment with QUTENZA
  13. to capsaicin (eg, chili peppers or over-the-counter capsaicin products) or any QUTENZA
  14. Active or history of malignancy during the past 5 years prior to screening visit (a history of squamous cell carcinoma or a basal cell carcinoma not involving the area to be treated is allowed)
  15. Use of transcutaneous nerve or spinal cord stimulators to relieve pain
  16. Patient, who in the opinion of the Investigator, is not likely to complete the study for any reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
144 participants (actual)
Patient registry
No

Groups and cohorts

  • Study group

    All subjects will receive repeat applications of the capsaicin 8% topical system every 12 weeks (up to 3 applications).

    Drug: Capsaicin 8%

Interventions

  • Repeat applications every 12 weeks in patients with PDPN of the feet.

06

What researchers measure

Primary outcomes

  1. Change (%) in pain intensity post QUTENZA administrations

    The pain intensity score from baseline will be compared to the average weekly pain intensity score between weeks 2-12 post each QUTENZA application (up to 3 applications).

    Time frame: Baseline, weeks 2-12 Post-Admin

  2. Change (%) in overall scores for Patient-Report Outcomes Measurement Information System (PROMIS)-29

    The baseline PROMIS-29 scores for all domains will be compared to the PROMIS-29 scores assessed at 12 weeks post-each QUTENZA application (up to 3 applications).

    Time frame: Baseline, week 12 Post-Admin

  3. Total number of patients who completed each QUTENZA treatment.

    Analysis of the number of patients who completed repeated (2 or 3) QUTENZA applications.

    Time frame: week 12 Post-Admin

  4. Change (%) of concomitant medications at baseline and 12 weeks after each treatment

    The change in utilization of pharmaceutical drug by medication, pharmacology class, dose, and frequency of use for drugs for PDPN, documented by collecting Concomitant medications including indication (for PDPN, for other reasons, and for temporary rescue use for PDPN) and dose

    Time frame: through study completion, an average of 36 weeks

07

Study locations

10 sites
  • Center for Interventional Pain and Spine
    Wilmington, Delaware 19808, United States
  • Horizon Clinical Research
    Gainesville, Georgia 30501, United States
  • Horizon Clinical Research
    Jasper, Georgia 30143, United States
  • Horizon Clinical Research
    Newnan, Georgia 30265, United States
  • Iqra Research
    Edgewood, Kentucky 41017, United States
  • Curalta Clinical Trials
    Oradell, New Jersey 07649, United States
  • Iqra Research
    Cincinnati, Ohio 45248, United States
  • Center for Interventional Pain and Spine
    Bryn Mawr, Pennsylvania 19010, United States
  • Center for Interventional Pain and Spine
    Fort Washington, Pennsylvania 19034, United States
  • Center for Interventional Pain and Spine
    Lancaster, Pennsylvania 17601, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 19 observational studies under Diabetic Neuropathies, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 10, 2024
StartActual
Mar 14, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06495424
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Mar 14, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion